Paratek Pharmaceuticals Inc Quick Ratio (PRTK) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Paratek Pharmaceuticals Inc   (NASDAQ: PRTK)

Paratek Pharmaceuticals Inc 's Quick Ratio

PRTK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Paratek Pharmaceuticals Inc 's Cash & cash equivalent grew by 31.47 % in the Q1 2023 sequentially, while Current Liabilities decreased, this led to improvement in Paratek Pharmaceuticals Inc 's Quick Ratio to 1.38, Quick Ratio remained below Paratek Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Paratek Pharmaceuticals Inc in first quarter 2023. While Quick Ratio total ranking has improved so far during the Q1 2023 to 1947, from total ranking in the fourth quarter 2022 at 2231.

Explain Quick Ratio?
How much Cash & cash equivalents PRTK´s has?
What are PRTK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRTK Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 13.55 % 19.46 % 33.71 % 43.49 % 25.61 %
Y / Y Cash & cash equivalent Change -43.04 % -64.13 % -48.64 % -7.84 % -23.58 %
Quick Ratio MRQ 1.38 0.92 1.46 2.31 2.74
PRTK's Total Ranking # 1947 # 2231 # 1687 # 1709 # 1251
Seq. Current Liabilities Change -12.42 % -4.07 % 29.49 % 4.38 % -7.86 %
Seq. Cash & cash equivalent Change 31.47 % -39.93 % -17.84 % -12.22 % -17.2 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 761
Overall Market # 1947


Quick Ratio Statistics
High Average Low
25.62 9.11 0.92
(Dec 31 2014)   (Dec 31 2022)




Financial Statements
Paratek Pharmaceuticals Inc 's Current Liabilities $ 33 Millions Visit PRTK's Balance sheet
Paratek Pharmaceuticals Inc 's Cash & cash equivalent $ 45 Millions Visit PRTK's Balance sheet
Source of PRTK's Sales Visit PRTK's Sales by Geography


Cumulative Paratek Pharmaceuticals Inc 's Quick Ratio

PRTK's Quick Ratio for the trailling 12 Months

PRTK Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 26.25 % 29.62 % 33.16 % 31.5 % 6.29 %
Y / Y Cash & cash equivalent TTM Growth -43 % -37.78 % -27.47 % -21.72 % -36.13 %
Quick Ratio TTM 1.48 1.77 2.33 2.97 3.27
Total Ranking TTM # 4452 # 4411 # 1135 # 3960 # 4248
Seq. Current Liabilities TTM Growth 2.89 % 4.71 % 8.23 % 8.27 % 5.63 %
Seq. Cash & cash equivalent TTM Growth -14.2 % -20.35 % -15.21 % -1.64 % -6.33 %

Quick ratio ranking by company, industry and sector >> Back to PRTK Financial Strength Comparisons >> Go to Compare PRTK Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q1 2023 to $32.75 millions, cumulative Quick Ratio decreased to 1.48 below the Paratek Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 584 other companies have achieved higher Quick Ratio than Paratek Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4411 to 4452.

Explain Quick Ratio?
How much Cash & cash equivalents PRTK´s has?
What are PRTK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 585
Healthcare Sector # 1163
Within the Market # 4452


trailing twelve months Quick Ratio Statistics
High Average Low
13.43 7.36 1.48
(Sep. 30, 2015)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Innoviva Inc   3.78 $ 144.049  Millions$ 38.137  Millions
Genprex Inc   3.74 $ 18.083  Millions$ 4.835  Millions
Canton Strategic Holdings Inc   3.71 $ 3.569  Millions$ 0.961  Millions
Vincerx Pharma Inc   3.71 $ 39.768  Millions$ 10.712  Millions
Tempest Therapeutics Inc   3.71 $ 22.925  Millions$ 6.186  Millions
Exicure Inc   3.65 $ 9.960  Millions$ 2.729  Millions
Vistagen Therapeutics Inc   3.64 $ 16.638  Millions$ 4.567  Millions
Arcturus Therapeutics Holdings Inc   3.64 $ 327.935  Millions$ 90.130  Millions
Gain Therapeutics inc  3.62 $ 17.816  Millions$ 4.922  Millions
Alterity Therapeutics Limited  3.60 $ 10.510  Millions$ 2.920  Millions
Galera Therapeutics Inc   3.60 $ 47.751  Millions$ 13.266  Millions
Abivax Sa  3.60 $ 282.175  Millions$ 78.447  Millions
Y mabs Therapeutics inc   3.57 $ 92.629  Millions$ 25.920  Millions
Bio path Holdings inc   3.52 $ 6.731  Millions$ 1.910  Millions
Revance Therapeutics Inc   3.52 $ 274.224  Millions$ 77.985  Millions
Adagene Inc   3.49 $ 109.934  Millions$ 31.456  Millions
Longeveron Inc   3.49 $ 10.593  Millions$ 3.039  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Acurx Pharmaceuticals inc   3.46 $ 7.179  Millions$ 2.074  Millions
G1 Therapeutics Inc   3.45 $ 116.317  Millions$ 33.690  Millions
Vertex Pharmaceuticals Inc  3.44 $ 10,414.100  Millions$ 3,026.200  Millions
Regulus Therapeutics Inc   3.44 $ 30.308  Millions$ 8.822  Millions
Trevena inc   3.42 $ 27.436  Millions$ 8.019  Millions
Alpine Immune Sciences Inc   3.41 $ 194.925  Millions$ 57.089  Millions
Notable Labs Ltd   3.41 $ 26.454  Millions$ 7.755  Millions
Biohaven Ltd   3.40 $ 388.029  Millions$ 114.006  Millions
Madrigal Pharmaceuticals Inc   3.37 $ 329.477  Millions$ 97.695  Millions
Bullfrog Ai Holdings Inc   3.37 $ 5.420  Millions$ 1.609  Millions
Regeneron Pharmaceuticals Inc   3.35 $ 8,959.700  Millions$ 2,673.800  Millions
Imunon Inc   3.32 $ 33.426  Millions$ 10.069  Millions

Date modified: 2026-09-26T07:07:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.